

Matthew J Price

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6172308/publications.pdf>

Version: 2024-02-01

218
papers

17,290
citations

34016

52
h-index

14156

128
g-index

255
all docs

255
docs citations

255
times ranked

12286
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical outcomes according to lesion complexity in high bleeding risk patients treated with 1â€month dual antiplatelet therapy following <scp>PCI</scp>: Analysis from the <scp>Onyx ONE</scp> clear study. Catheterization and Cardiovascular Interventions, 2022, 99, 583-592.	0.7	3
2	Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS120010390.	1.4	4
3	Sex-Specific Outcomes After Coronary Intravascular Lithotripsy: Aâ€Patient-Level Analysis of the Disrupt CAD Studies. , 2022, 1, 100011.		3
4	Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS121011069.	1.4	0
5	Clinical Outcomes at 1 Year Following Transcatheter Left Atrial Appendage Occlusion in the United States. JACC: Cardiovascular Interventions, 2022, 15, 741-750.	1.1	19
6	Periprocedural Pericardial Effusion Complicating Transcatheter Left Atrial Appendage Occlusion: A Report From the NCDR LAO Registry. Circulation: Cardiovascular Interventions, 2022, 15, .	1.4	14
7	Letter by Price et al Regarding the Article, â€œAmplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trialâ€ Circulation, 2022, 145, e849.	1.6	0
8	Patient-Level Analysis of Watchman Left Atrial Appendage Occlusion in Practice Versus Clinical Trials. JACC: Cardiovascular Interventions, 2022, 15, 950-961.	1.1	11
9	Antithrombotic Therapy After Leftâ€Atrialâ€Appendage Occlusion in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2022, 79, 1785-1798.	1.2	42
10	Polymer-Based Versus Polymer-Free Stents in High Bleeding Risk Patients. JACC: Cardiovascular Interventions, 2022, 15, 1153-1163.	1.1	10
11	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. Circulation, 2021, 143, 583-596.	1.6	119
12	Primary Results of the EVOLVE Short DAPT Study. Circulation: Cardiovascular Interventions, 2021, 14, e010144.	1.4	48
13	Intravascular Lithotripsy for Treatment of Calcified Coronary Lesions. JACC: Cardiovascular Interventions, 2021, 14, 1337-1348.	1.1	66
14	Efficacy and safety of cangrelor in patients with peripheral artery disease undergoing percutaneous coronary intervention â€“ Insights from the CHAMPION program. American Heart Journal Plus, 2021, 9, 100043.	0.3	0
15	Treatment and Outcomes of Device-Related Thrombus After Transcatheter Left Atrial Appendage Closure. Circulation: Cardiovascular Interventions, 2021, 14, e010889.	1.4	1
16	Risk of thromboembolic events after percutaneous left atrial appendage ligation in patients with atrial fibrillation: Long-term results of a multicenter study. Heart Rhythm, 2020, 17, 175-181.	0.3	38
17	Abbreviated Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in High Bleeding Risk Patients. Interventional Cardiology Clinics, 2020, 9, 441-449.	0.2	0
18	Intravascular Lithotripsy for Treatment of Severely Calcified Coronaryâ€Artery Disease. Journal of the American College of Cardiology, 2020, 76, 2635-2646.	1.2	209

#	ARTICLE	IF	CITATIONS
19	One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009565.	1.4	49
20	Use of a Novel Septal Occluder Device for Left Atrial Appendage Closure in Patients With Postsurgical and Postlariat Leaks or Anatomies Unsuitable for Conventional Percutaneous Occlusion. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009227.	1.4	11
21	Global Approach to High Bleeding Risk Patients With Polymer-Free Drug-Coated Coronary Stents. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e008603.	1.4	28
22	Diagnostic Accuracy of Nonhyperemic Pressure Ratios Using a Pressure Sensing Microcatheter. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1272-1275.	1.1	1
23	Transcatheter Left Atrial Appendage Occlusion in the DOAC Era. <i>Journal of the American College of Cardiology</i> , 2020, 75, 3136-3139.	1.2	7
24	A Pilot Study of Monotherapy with a Non-Vitamin K-Antagonist Oral Anticoagulant following Watchman Left Atrial Appendage Closure in Patients with Non-Valvular Atrial Fibrillation. <i>Structural Heart</i> , 2020, 4, 288-292.	0.2	2
25	Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 606-617.	1.1	90
26	Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk. <i>New England Journal of Medicine</i> , 2020, 382, 1208-1218.	13.9	207
27	The NCDR Left Atrial Appendage Occlusion Registry. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1503-1518.	1.2	237
28	Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007342.	1.4	10
29	The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX. <i>Clinical Cardiology</i> , 2019, 42, 797-805.	0.7	4
30	Transcatheter Edge-to-Edge Repair for Primary (Degenerative) Mitral Regurgitation. <i>Interventional Cardiology Clinics</i> , 2019, 8, 245-259.	0.2	3
31	Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1521-1537.	1.1	366
32	Transcatheter Mitral Valve Repair and Replacement: New Standards of Care and New Horizons for Therapy. <i>Interventional Cardiology Clinics</i> , 2019, 8, xi-xii.	0.2	0
33	Rationale and design of the Onyx ONE global randomized trial: A randomized controlled trial of high-bleeding risk patients after stent placement with 1 month of dual antiplatelet therapy. <i>American Heart Journal</i> , 2019, 214, 134-141.	1.2	31
34	Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. <i>European Heart Journal</i> , 2019, 40, 2632-2653.	1.0	335
35	Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2019, 140, 240-261.	1.6	428
36	Device-Related Thrombus After Transcatheter Left Atrial Appendage Closure. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1015-1017.	1.1	3

#	ARTICLE	IF	CITATIONS
37	Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y ₁₂ Inhibitor Pretreatment. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007445.	1.4	0
38	EFFECT OF TRANSCATHETER MITRAL VALVE REPAIR ON HEART FAILURE MANAGEMENT AND PULMONARY ARTERY PRESSURES AS ASSESSED BY CARDIOMEMS. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2003.	1.2	0
39	Percutaneous Coronary Intervention Gathers No Moss. <i>Interventional Cardiology Clinics</i> , 2019, 8, ix.	0.2	0
40	Newer-generation Metallic Stents. <i>Interventional Cardiology Clinics</i> , 2019, 8, 95-109.	0.2	4
41	Full Revascularization in the Patient With ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2724-2727.	1.2	5
42	Characteristics and outcomes of patients requiring bailout use of glycoprotein IIb/IIIa inhibitors for thrombotic complications of percutaneous coronary intervention: An analysis from the CHAMPION PHOENIX trial. <i>International Journal of Cardiology</i> , 2019, 278, 217-222.	0.8	6
43	Thromboembolic events and need for anticoagulation therapy following left atrial appendage occlusion in patients with electrical isolation of the appendage. <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, 511-516.	0.8	21
44	The functional assessment of patients with non-obstructive coronary artery disease: expert review from an international microcirculation working group. <i>EuroIntervention</i> , 2019, 14, 1694-1702.	1.4	32
45	Current State of Left Atrial Appendage Closure. <i>Current Cardiology Reports</i> , 2018, 20, 42.	1.3	9
46	Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e005635.	1.4	13
47	Modernizing the World Health Organization List of Essential Medicines for Preventing and Controlling Cardiovascular Diseases. <i>Journal of the American College of Cardiology</i> , 2018, 71, 564-574.	1.2	40
48	Safety and Efficacy of Transcatheter Left Atrial Appendage Closure for Stroke Prevention in Patients with Atrial Fibrillation. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 542-549.	1.6	7
49	Pharmacogenomic Testing to Select Antiplatelet Therapy. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1878-1881.	1.2	6
50	The WATCHMAN Left Atrial Appendage Closure Device. <i>Interventional Cardiology Clinics</i> , 2018, 7, 201-212.	0.2	7
51	Left Atrial Appendage Occlusion. <i>Interventional Cardiology Clinics</i> , 2018, 7, 159-168.	0.2	4
52	Percutaneous closure of patent foramen ovale vs. medical treatment for patients with history of cryptogenic stroke: A systematic review and meta-analysis of randomized controlled trials. <i>Cardiovascular Revascularization Medicine</i> , 2018, 19, 852-858.	0.3	15
53	Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 158-165.	0.4	7
54	Cangrelor compared with clopidogrel in patients with prior myocardial infarction – Insights from the CHAMPION trials. <i>International Journal of Cardiology</i> , 2018, 250, 49-55.	0.8	5

#	ARTICLE	IF	CITATIONS
55	Safety and efficacy of the next generation Resolute Onyx zotarolimus-eluting stent: Primary outcome of the RESOLUTE ONYX core trial. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 253-259.	0.7	26
56	Left Atrial Appendage Therapies. , 2018, , 473-487.		0
57	TCT-841 Baseline characteristics and 3-month outcomes of the EVOLVE Short DAPT Trial: A prospective investigation of abbreviated antiplatelet therapy in high bleeding risk patients treated with a thin-strut bioabsorbable polymer-coated, everolimus-eluting coronary stent. <i>Journal of the American College of Cardiology</i> , 2018, 72, B335-B336.	1.2	0
58	Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10,854 patients from the CHAMPION PHOENIX trial. <i>European Heart Journal</i> , 2018, 39, 4112-4121.	1.0	49
59	Response by Angiolillo et al to Letter Regarding Article, "International Expert Consensus Document on Switching Platelet P2Y ₁₂ Receptor Inhibiting Therapies". <i>Circulation</i> , 2018, 137, 2310-2311.	1.6	2
60	Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention. <i>Circulation</i> , 2018, 138, 527-536.	1.6	211
61	New Volumetric Analysis Method for Stent Expansion and its Correlation With Final Fractional Flow Reserve and Clinical Outcome. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1467-1478.	1.1	34
62	Imaging in Intervention. <i>Interventional Cardiology Clinics</i> , 2018, 7, xi.	0.2	0
63	Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention. <i>American Heart Journal</i> , 2018, 205, 110-117.	1.2	22
64	Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials. <i>International Journal of Cardiology</i> , 2018, 270, 96-101.	0.8	10
65	Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials. <i>EuroIntervention</i> , 2018, 13, e1841-e1849.	1.4	16
66	Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 190-198.	0.7	18
67	Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2017, 69, 176-185.	1.2	47
68	Synthesis and Characterization of 2-Phenylimidazo[1,2-a]pyridine: A Privileged Structure for Medicinal Chemistry. <i>Journal of Chemical Education</i> , 2017, 94, 388-391.	1.1	8
69	ANTARCTIC: platelet function testing to adjust therapy. <i>Lancet, The</i> , 2017, 389, 1193.	6.3	3
70	Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors. <i>JAMA Cardiology</i> , 2017, 2, 127.	3.0	36
71	Cangrelor. <i>Interventional Cardiology Clinics</i> , 2017, 6, 39-47.	0.2	5
72	TWELVE MONTH FOLLOW-UP DATA FROM THE ONYX CORE TRIAL: ANGIOGRAPHIC AND CLINICAL PERFORMANCE OF NEXT GENERATION RESOLUTE ONYX DRUG-ELUTING STENT. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1110.	1.2	0

#	ARTICLE	IF	CITATIONS
73	Cangrelor reduces the risk of ischemic complications in patients with single-vessel and multi-vessel disease undergoing percutaneous coronary intervention: Insights from the CHAMPION PHOENIX trial. American Heart Journal, 2017, 188, 147-155.	1.2	2
74	Antiplatelet and Anticoagulation Therapy in Percutaneous Coronary Intervention. Interventional Cardiology Clinics, 2017, 6, xi-xii.	0.2	0
75	Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	6
76	International Expert Consensus on Switching Platelet P2Y ₁₂ Receptor-Inhibiting Therapies. Circulation, 2017, 136, 1955-1975.	1.6	293
77	Imaging Assessment of the Interatrial Septum for Transcatheter Atrial Septal Defect and Patent Foramen Ovale Closure. Interventional Cardiology Clinics, 2017, 6, 505-524.	0.2	7
78	Transcatheter Closure of Patent Foramen Ovale. Interventional Cardiology Clinics, 2017, 6, ix-x.	0.2	1
79	Transcatheter Closure of Patent Foramen Ovale. Interventional Cardiology Clinics, 2017, 6, 555-567.	0.2	8
80	Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION). Thrombosis and Haemostasis, 2017, 117, 1093-1100.	0.7	12
81	First Report of the Resolute Onyx 2.0-mm Zotarolimus-Eluting Stent for the Treatment of Coronary Lesions With Very Small Reference Vessel Diameter. JACC: Cardiovascular Interventions, 2017, 10, 1381-1388.	1.1	50
82	Cangrelor in Older Patients Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	7
83	5-Year Outcomes After Left Atrial Appendage Closure. Journal of the American College of Cardiology, 2017, 70, 2964-2975.	1.2	725
84	Use of non-warfarin oral anticoagulants instead of warfarin during left atrial appendage closure with the Watchman device. Heart Rhythm, 2017, 14, 19-24.	0.3	96
85	Assessing the Safety of Early U.S. Commercial Application of Left Atrial Appendage Closure. Journal of the American College of Cardiology, 2017, 69, 262-264.	1.2	10
86	Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study. Thrombosis and Haemostasis, 2017, 117, 1093-1100.	1.8	9
87	ACIST-FFR Study (Assessment of Catheter-Based Interrogation and Standard Techniques for Fractional). Thrombosis and Haemostasis, 2017, 117, 1093-1100.	1.4	37
88	IMPACT OF PRIOR CEREBROVASCULAR EVENTS ON ISCHEMIC AND BLEEDING OUTCOMES WITH CANGRELOR IN PERCUTANEOUS CORONARY INTERVENTION. Journal of the American College of Cardiology, 2016, 67, 198.	1.2	0
89	Cardiovascular Interventions in the Modern Age. JACC: Cardiovascular Interventions, 2016, 9, 1083-1084.	1.1	0
90	Off-Hours Versus On-Hours Presentation in ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2016, 68, 2385-2387.	1.2	6

#	ARTICLE	IF	CITATIONS
91	Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions. <i>Circulation</i> , 2016, 134, 723-733.	1.6	31
92	Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1905-1913.	1.1	38
93	Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	83
94	The Pharmacodynamics of Switching Between P2Y12 Receptor Antagonists. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1099-1101.	1.1	1
95	Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, .	1.4	10
96	Clinical Implications of Leaks Following Left Atrial Appendage Ligation With the LARIAT Device. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1051-1057.	1.1	45
97	Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention. <i>Circulation</i> , 2016, 133, 248-255.	1.6	26
98	Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding. <i>Journal of the American College of Cardiology</i> , 2016, 67, 596-598.	1.2	25
99	PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 374-383.	1.0	32
100	The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX. <i>European Heart Journal</i> , 2016, 37, 1122-1130.	1.0	23
101	WATCHMAN: Trials and Registries Results. <i>Contemporary Cardiology</i> , 2016, , 169-180.	0.0	0
102	Catheter-Based Left Atrial Appendage Closure. , 2016, , 107-117.		0
103	A review of the LARIAT device: insights from the cumulative clinical experience. <i>SpringerPlus</i> , 2015, 4, 522.	1.2	22
104	Randomized Controlled Trial of Home-Based Telehealth Versus In-Person Prolonged Exposure for Combat-Related PTSD in Veterans: Preliminary Results. <i>Journal of Clinical Psychology</i> , 2015, 71, 500-512.	1.0	110
105	Left atrial appendage closure—facing the truth and forging the future. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 313-314.	0.7	0
106	Bleeding Outcomes After Left Atrial Appendage Closure Compared With Long-Term Warfarin. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1925-1932.	1.1	84
107	Risk Assessment in Patient Selection for Transcatheter Aortic Valve Replacement. <i>Interventional Cardiology Clinics</i> , 2015, 4, 1-12.	0.2	4
108	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 65, 405-406.	1.2	1

#	ARTICLE	IF	CITATIONS
109	Impingement of Left Main Ostium After Device Occlusion of Paravalvular Leak Post-Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, e1-e2.	1.1	0
110	Optical coherence tomography imaging during percutaneous coronary intervention impacts physician decision-making: ILUMIEN I study. <i>European Heart Journal</i> , 2015, 36, 3346-3355.	1.0	197
111	Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2614-2623.	1.2	470
112	AN INVESTIGATION OF OUTCOME EXPECTANCIES AS A PREDICTOR OF TREATMENT RESPONSE FOR COMBAT VETERANS WITH PTSD: COMPARISON OF CLINICIAN, SELF-REPORT, AND BIOLOGICAL MEASURES. <i>Depression and Anxiety</i> , 2015, 32, 392-399.	2.0	27
113	Bleeding and stent thrombosis on P2Y ₁₂ -inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. <i>European Heart Journal</i> , 2015, 36, 1762-1771.	1.0	297
114	Update on the Guidelines for the Management of ST-Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2015, 115, 3A-9A.	0.7	14
115	A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 8-14.	1.0	13
116	Outcomes With Cangrelor Versus Clopidogrel on a Background of Bivalirudin. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 424-433.	1.1	35
117	The Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1311-1313.	1.2	4
118	Percutaneous Left Atrial Appendage Ligation for Stroke Prevention in Atrial Fibrillation. <i>Methodist DeBakey Cardiovascular Journal</i> , 2015, 11, 94-99.	0.5	1
119	Platelet inhibition with ticagrelor versus clopidogrel in Hispanic patients with stable coronary artery disease with or without diabetes mellitus. <i>Cardiovascular Revascularization Medicine</i> , 2015, 16, 450-454.	0.3	12
120	Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 317-322.	1.0	26
121	TCT-75 Cangrelor Improves Ischemic Outcomes In Patients With Multivessel Disease And Single Vessel Disease Undergoing PCI: Insights From The CHAMPION PHOENIX Trial. <i>Journal of the American College of Cardiology</i> , 2015, 66, B35.	1.2	0
122	Safety and Efficacy of Cangrelor, an Intravenous, Short-Acting Platelet Inhibitor in Patients Requiring Coronary Artery Bypass Surgery. <i>Heart Surgery Forum</i> , 2015, 16, 60.	0.2	6
123	Cangrelor for treatment of arterial thrombosis. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 565-572.	0.9	4
124	Conversations in Cardiology. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, 748-752.	0.7	1
125	Detecting a thienopyridine effect by platelet reactivity assessment and its implications for risk stratification. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 560-563.	1.9	4
126	Percutaneous management of late leak after lariat transcatheter ligation of the left atrial appendage in patients with atrial fibrillation at high risk for stroke. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, 664-669.	0.7	35

#	ARTICLE	IF	CITATIONS
127	mHealth: A Mechanism to Deliver More Accessible, More Effective Mental Health Care. <i>Clinical Psychology and Psychotherapy</i> , 2014, 21, 427-436.	1.4	398
128	Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2014, 63, 619-629.	1.2	92
129	Prevention and Management of Complications of Left Atrial Appendage Closure Devices. <i>Interventional Cardiology Clinics</i> , 2014, 3, 301-311.	0.2	8
130	Diabetes Mellitus and Clopidogrel Response Variability. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1015-1018.	1.2	8
131	Early Safety and Efficacy of Percutaneous Left Atrial Appendage Suture Ligation. <i>Journal of the American College of Cardiology</i> , 2014, 64, 565-572.	1.2	200
132	Left Atrial Appendage Closure to Prevent Stroke in Patients With Atrial Fibrillation. <i>Circulation</i> , 2014, 130, 202-212.	1.6	32
133	Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1-12.	1.2	1,605
134	Mechanical closure devices for atrial fibrillation. <i>Trends in Cardiovascular Medicine</i> , 2014, 24, 225-231.	2.3	2
135	Examination of Prior Experience with Telehealth and Comfort with Telehealth Technology as a Moderator of Treatment Response for PTSD and Depression in Veterans. <i>International Journal of Psychiatry in Medicine</i> , 2014, 48, 57-67.	0.8	35
136	Left Atrial Appendage Occlusion With the WATCHMAN for Stroke Prevention in Atrial Fibrillation. <i>Reviews in Cardiovascular Medicine</i> , 2014, 15, 142-151.	0.5	7
137	Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2261-2273.	1.2	807
138	Platelet reactivity after coronary stenting. <i>Lancet</i> , 2013, 382, 583-584.	6.3	2
139	Platelet Function and Genetic Testing. <i>Journal of the American College of Cardiology</i> , 2013, 62, S21-S31.	1.2	28
140	Pharmacogenomics in Interventional Pharmacology. <i>Interventional Cardiology Clinics</i> , 2013, 2, 615-625.	0.2	2
141	Percutaneous Closure of Paravalvular Leak After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, e6-e8.	1.1	15
142	Platelet Function Monitoring and Clopidogrel. <i>Current Cardiology Reports</i> , 2013, 15, 321.	1.3	9
143	Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events. <i>New England Journal of Medicine</i> , 2013, 368, 1303-1313.	13.9	695
144	Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: Systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2013, 167, 2140-2148.	0.8	113

#	ARTICLE	IF	CITATIONS
145	The role of clopidogrel in the management of ischemic heart disease. <i>Current Opinion in Cardiology</i> , 2013, 28, 381-388.	0.8	0
146	PREDICTORS OF COMPLETION OF EXPOSURE THERAPY IN OEF/OIF VETERANS WITH POSTTRAUMATIC STRESS DISORDER. <i>Depression and Anxiety</i> , 2013, 30, 1107-1113.	2.0	46
147	Retrospective multicenter observational study of the interventional management of coronary disease in the very elderly: The NINETY. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 82, 414-421.	0.7	10
148	Evaluating the clinical usefulness of platelet function testing: Considerations for the proper application and interpretation of performance measures. <i>Thrombosis and Haemostasis</i> , 2013, 109, 808-816.	1.8	32
149	Bridging Antiplatelet Therapy With Cangrelor in Patients Undergoing Cardiac Surgery. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 265-74.	3.8	386
150	Measured Drug Effect and Cardiovascular Outcomes in Patients Receiving Platelet P2Y ₁₂ Receptor Antagonists. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1806.	3.8	7
151	Response to Letters Regarding Article, "Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y ₁₂ Assay: Impact on Thrombosis and Safety (GRAVITAS) Trial". <i>Circulation</i> , 2012, 125, .	1.6	1
152	Behavioral Activation and Therapeutic Exposure: An Investigation of Relative Symptom Changes in PTSD and Depression During the Course of Integrated Behavioral Activation, Situational Exposure, and Imaginal Exposure Techniques. <i>Behavior Modification</i> , 2012, 36, 580-599.	1.1	78
153	Left atrial appendage occlusion for the reduction of stroke and embolism in patients with atrial fibrillation. <i>Journal of Cardiovascular Medicine</i> , 2012, 13, 131-137.	0.6	3
154	Outcome expectancy as a predictor of treatment response in cognitive behavioral therapy for public speaking fears within social anxiety disorder.. <i>Psychotherapy</i> , 2012, 49, 173-179.	0.7	85
155	Prolonged exposure therapy for combat-related posttraumatic stress disorder: Comparing outcomes for veterans of different wars.. <i>Psychological Services</i> , 2012, 9, 16-25.	0.9	62
156	Genetic Considerations. <i>Advances in Cardiology</i> , 2012, 47, 100-113.	2.6	3
157	Symptom overlap in posttraumatic stress disorder and major depression. <i>Psychiatry Research</i> , 2012, 196, 267-270.	1.7	144
158	The effect of exercise absence on affect and body dissatisfaction as moderated by obligatory exercise beliefs and eating disordered beliefs and behaviors. <i>Psychology of Sport and Exercise</i> , 2012, 13, 500-508.	1.1	20
159	Rationale and design of the Cangrelor versus standard therapy to achieve optimal Management of Platelet Inhibition PHOENIX trial. <i>American Heart Journal</i> , 2012, 163, 768-776.e2.	1.2	72
160	Influence of Genetic Polymorphisms on the Effect of High- and Standard-Dose Clopidogrel After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1928-1937.	1.2	127
161	Left Main Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1605-1613.	1.2	26
162	Recovery of Platelet Function After Discontinuation of Prasugrel or Clopidogrel Maintenance Dosing in Aspirin-Treated Patients With Stable Coronary Disease. <i>Journal of the American College of Cardiology</i> , 2012, 59, 2338-2343.	1.2	104

#	ARTICLE	IF	CITATIONS
163	Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 44-55.	1.0	131
164	Mindfulness Moderates the Relationship Between Disordered Eating Cognitions and Disordered Eating Behaviors in a Non-Clinical College Sample. <i>Journal of Psychopathology and Behavioral Assessment</i> , 2012, 34, 107-115.	0.7	55
165	Platelet Inhibitor Agents. , 2012, , 97-112.		2
166	Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention. <i>Circulation</i> , 2011, 124, 1132-1137.	1.6	381
167	Impact of Platelet Reactivity on Clinical Outcomes After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1945-1954.	1.2	383
168	The impact of cognitive behavioral therapy on post event processing among those with social anxiety disorder. <i>Behaviour Research and Therapy</i> , 2011, 49, 132-137.	1.6	63
169	Psychological flexibility mediates the relations between self-concealment and negative psychological outcomes. <i>Personality and Individual Differences</i> , 2011, 50, 243-247.	1.6	49
170	Clinical outcomes following predilation with a novel 1.25â€mm diameter angioplasty catheter. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 77, 510-514.	0.7	5
171	Functional testing methods for the antiplatelet effect of P2Y12receptor antagonists. <i>Biomarkers in Medicine</i> , 2011, 5, 43-51.	0.6	11
172	Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1097.	3.8	1,185
173	Standard- vs High-Dose Clopidogrel After Percutaneous Coronary Interventionâ€”Reply. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 2520.	3.8	1
174	Platelet-Mediated Thrombosis and Drug-Eluting Stents. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 629-637.	1.4	7
175	The Influence of CYP2C19 Polymorphisms on the Pharmacokinetics, Pharmacodynamics, and Clinical Effectiveness of P2Y12 Inhibitors. <i>Reviews in Cardiovascular Medicine</i> , 2011, 12, 1-12.	0.5	24
176	The Brave New World of Antiplatelet Therapy: Seeking Clarity in a World of Increasing Choice and Complexity. <i>Reviews in Cardiovascular Medicine</i> , 2011, 12, 1-3.	0.5	32
177	Utility of onâ€line threeâ€dimensional transesophageal echocardiography during percutaneous atrial septal defect closure. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 570-577.	0.7	16
178	Threeâ€year outcome of drugâ€eluting stent implantation for coronary artery bifurcation lesions. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 309-314.	0.7	21
179	A novel technique for ultraâ€low contrast administration during angiography or intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 1076-1083.	0.7	52
180	Pilot Study of the Antiplatelet Effect of Increased Clopidogrel Maintenance Dosing and Its Relationship to CYP2C19 Genotype in Patients With High On-Treatment Reactivity. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 1001-1007.	1.1	38

#	ARTICLE	IF	CITATIONS
181	The Evidence Base for Platelet Function Testing in Patients Undergoing Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2010, 3, 277-283.	1.4	10
182	Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine Diphosphate. <i>Journal of the American College of Cardiology</i> , 2010, 56, 919-933.	1.2	1,058
183	IMPACT OF PLATELET REACTIVITY ON CLINICAL OUTCOMES: A PATIENT LEVEL META-ANALYSIS. <i>Journal of the American College of Cardiology</i> , 2010, 55, A179.E1673.	1.2	2
184	Bedside Evaluation of Thienopyridine Antiplatelet Therapy. <i>Circulation</i> , 2009, 119, 2625-2632.	1.6	118
185	Safety and Performance of Targeted Renal Therapy: The Be-RITe! Registry. <i>Journal of Endovascular Therapy</i> , 2009, 16, 1-12.	0.8	87
186	Monitoring Platelet Function to Reduce the Risk of Ischemic and Bleeding Complications. <i>American Journal of Cardiology</i> , 2009, 103, 35A-39A.	0.7	31
187	Relation of Periprocedural Bleeding Complications and Long-Term Outcome in Patients Undergoing Percutaneous Coronary Revascularization (from the Evaluation of Oral Xemilofiban in Controlling) <i>Tj ETQq1 1 0.784314 rgBT1/Overlook</i>	0.7	138
188	Predictors of Heightened Platelet Reactivity Despite Dual-Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2009, 103, 1339-1343.	0.7	138
189	Identifying the "Optimal" Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 1279-1285.	1.1	34
190	Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: Design and rationale of the GRAVITAS trial. <i>American Heart Journal</i> , 2009, 157, 818-824.e1.	1.2	110
191	The Role of Psychological Flexibility in Mental Health Stigma and Psychological Distress for the Stigmatizer. <i>Journal of Social and Clinical Psychology</i> , 2009, 28, 1244-1262.	0.2	50
192	Antiplatelet therapy in acute coronary syndromes. <i>Current Cardiology Reports</i> , 2008, 10, 327-333.	1.3	5
193	The off-versus on-label use of medical devices in interventional cardiovascular medicine: Clarifying the ambiguity between regulatory labeling and clinical decision-making, Part 1: PCI. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 72, 500-504.	0.7	8
194	Dynamics of Platelet Functional Recovery Following a Clopidogrel Loading Dose in Healthy Volunteers. <i>American Journal of Cardiology</i> , 2008, 102, 790-795.	0.7	28
195	Greater Expectations: Using Hierarchical Linear Modeling to Examine Expectancy for Treatment Outcome as a Predictor of Treatment Response. <i>Behavior Therapy</i> , 2008, 39, 398-405.	1.3	71
196	Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. <i>European Heart Journal</i> , 2008, 29, 992-1000.	1.0	593
197	A collaborative systematic review and meta-analysis on 1278 patients undergoing percutaneous drug-eluting stenting for unprotected left main coronary artery disease. <i>American Heart Journal</i> , 2008, 155, 274-283.	1.2	170
198	New antiplatelet therapies in development. <i>American Journal of Health-System Pharmacy</i> , 2008, 65, S11-S15.	0.5	2

#	ARTICLE	IF	CITATIONS
199	'A threshold of platelet reactivity for ischaemic events?' and 'The optimal threshold of high post-treatment platelet reactivity could be defined by a point-of care VerifyNow P2Y12 assay': reply. <i>European Heart Journal</i> , 2008, 29, 2187-2187.	1.0	0
200	Change We Can Believe In: The Hyper-Evolution of Percutaneous Coronary Intervention for Unprotected Left Main Disease With Drug-Eluting Stents. <i>Circulation: Cardiovascular Interventions</i> , 2008, 1, 164-166.	1.4	3
201	Diesel Engine Turbocharger Rebuild and Experimental Testing. , 2007, , 485.		0
202	The effect of granulocyte colony stimulating factor on regional and global myocardial function in the porcine infarct model. <i>International Journal of Cardiology</i> , 2007, 116, 225-230.	0.8	13
203	Clopidogrel Desensitization After Drug-Eluting Stent Placement. <i>Journal of the American College of Cardiology</i> , 2007, 50, 2039-2043.	1.2	45
204	Intracoronary radiation therapy for multi-drug resistant in-stent restenosis: Initial clinical experience. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 69, 132-134.	0.7	12
205	Efficacy and Safety of Triple Antiplatelet Therapy With and Without Concomitant Anticoagulation During Elective Percutaneous Coronary Intervention (the REMOVE Trial). <i>American Journal of Cardiology</i> , 2007, 100, 1099-1102.	0.7	19
206	Serial Angiographic Follow-Up of Sirolimus-Eluting Stents for Unprotected Left Main Coronary Artery Revascularization. <i>Journal of the American College of Cardiology</i> , 2006, 47, 871-877.	1.2	195
207	Intravenous mesenchymal stem cell therapy early after reperfused acute myocardial infarction improves left ventricular function and alters electrophysiologic properties. <i>International Journal of Cardiology</i> , 2006, 111, 231-239.	0.8	175
208	Unprotected Left Main Coronary Intervention with Drug-Eluting Stents. <i>Journal of Interventional Cardiology</i> , 2006, 19, S21-S26.	0.5	4
209	Rescue Percutaneous Coronary Intervention Early After Coronary Artery Bypass Grafting in the Drug-Eluting Stent Era. <i>American Journal of Cardiology</i> , 2006, 97, 789-791.	0.7	8
210	Differential Effects Between Intravenous and Targeted Renal Delivery of Fenoldopam on Renal Function and Blood Pressure in Patients Undergoing Cardiac Catheterization. <i>American Journal of Cardiology</i> , 2006, 97, 1076-1081.	0.7	40
211	Onset and Offset of Platelet Inhibition After High-Dose Clopidogrel Loading and Standard Daily Therapy Measured by a Point-of-Care Assay in Healthy Volunteers. <i>American Journal of Cardiology</i> , 2006, 98, 681-684.	0.7	130
212	Early- and Medium-Term Outcomes After Paclitaxel-Eluting Stent Implantation for Sirolimus-Eluting Stent Failure. <i>American Journal of Cardiology</i> , 2006, 98, 1345-1348.	0.7	30
213	Direct thrombin inhibition appears to be a safe and effective anticoagulant for percutaneous bypass graft interventions. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 68, 352-356.	0.7	8
214	Utility of three-dimensional reconstruction of coronary angiography to guide percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 69, 479-482.	0.7	63
215	A multicenter, randomized, dose-finding study of gamma intracoronary radiation therapy to inhibit recurrent restenosis after stenting. <i>Journal of Invasive Cardiology</i> , 2006, 18, 169-73.	0.4	2
216	Clinical outcomes after sirolimus-eluting stent implantation for de novo saphenous vein graft lesions. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 65, 208-211.	0.7	28

#	ARTICLE	IF	CITATIONS
217	Mending the broken heart. <i>Clinical Cardiology</i> , 2003, 26, 449-450.	0.7	2
218	Stem Cell Repair of Infarcted Myocardium. <i>Circulation</i> , 2003, 108, 1139-1145.	1.6	149